Recurrent visual field progression ‘frequent’ in glaucoma

Recurrent visual field progression in glaucoma was “frequent” and most likely to occur in eyes with faster progression, higher IOP or less damage at initial progression, according to data published in JAMA Ophthalmology.
“Clinical trials have demonstrated that approximately 12% to 45% of patients with treated glaucoma experience continued disease progression,” Davina A. Malek, MD, clinical research fellow at Bascom Palmer Eye Institute, and colleagues wrote. “Given the chronic nature of glaucoma and increasing longevity of the population, many patients may

Experts consider latest vitreoretinal surgical systems

Click here to read the Healio Exclusive, "Retina board addresses potential therapies for geographic atrophy, inherited diseases."
Led by Section Editor Andrew A. Moshfeghi, MD, MBA, Healio | OSN Retina/Vitreous Board Members discussed the latest generation of surgical systems for vitreoretinal surgeons.
They highlighted the platforms and the challenges associated with upgrading systems.
Moshfeghi: Is anyone using the Unity system from Alcon?
Jennifer I. Lim, MD, FARVO, FASRS: The department of ophthalmology and visual sciences at University of Illinois is purchasing a Unity system, hopefully

Proteomic age acceleration linked to symptom severity in MS

SAN DIEGO — A gap between proteomic age and chronological age may provide information on how likely an individual is to see MS progression before symptom onset as well as how severe symptoms might be, according to a presenter.
Because the signal given by the proteomic age gap is pre-symptomatic, it raises the possibility of early MS detection in high-risk populations, Fatemeh Siavoshi, MD, a neurology postdoctoral research fellow at Johns Hopkins University School of Medicine, said at the American Neurological Association’s 151st annual meeting.
“This could inform how often we monitor

Clinical collaboration aims to evaluate peptides

The Andrews Research & Education Foundation and Vector Science and Therapeutics announced a collaboration to advance the clinical evaluation of peptides for use in sports and regenerative medicine, according to a company press release.
“Putting the two teams together, our job with Andrews Research & Education Foundation is to conduct research to prove what peptides do or do not do,” James R. Andrews, MD, president and chair of the board of the Andrews Research & Education Foundation, told Healio. “There is no clinical research that has been performed in well controlled, double

Effective treatments in IgA nephropathy prompt new questions

In this video, Mark Haas, MD, PhD, reviews current updates and issues in immunoglobulin A nephropathy care that were discussed at ASN Kidney Week.
In response to the increase of effective treatments for IgA nephropathy, new questions about treatment duration and use of sequential or multiple drug therapies have emerged, according to Haas, renal pathologist and professor of pathology and laboratory services at Cedars-Sinai Medical Center in Los Angeles.
“There is a lot of optimism moving forward for patients with IgA nephropathy now that we have effective treatments for this disease. ... There’s

Dietary supplements can be source of resistant bacteria, investigation shows

WASHINGTON — Researchers at IDWeek presented findings from the CDC investigation that traced the first known U.S. outbreak of carbapenem-resistant Salmonella infections to dietary supplements containing moringa leaf powder.
“You can imagine we tend to focus on things like foods, chicken, eggs and animal exposures because those are the common culprits for Salmonella outbreaks in the United States, but it’s definitely possible that we have gaps,” Louise Francois Watkins, MD, MPH, a medical officer in CDC’s Division of Foodborne, Waterborne and Environmental Diseases, said during a presentation.

White House withdraws FDA commissioner nomination

The White House is searching once more for a new FDA commissioner after rescinding its pick, Heidi Overton, MD, according to reporting from the Associated Press.
The previous FDA commissioner, Martin Makary, MD, MPH, resigned his position in May. Since then, Kyle Diamantas, JD, has led the FDA as acting commissioner.
In August, President Donald J. Trump announced Overton, who was working as deputy assistant to the president for domestic policy, as his new pick to lead the administration. In September, the Senate Health, Education, Labor and Pensions committee questioned Overton on vaccines,

Changes to rotavirus vaccine guidance could reverse ‘decades of progress’

Based on analytical projections, “decades of progress in rotavirus disease prevention are at risk of reversal” if the CDC rescinds its routine rotavirus vaccine recommendation in infants, according to researchers.
The CDC has recommended routine rotavirus vaccination in infants — either as a two-dose series with RV1 (Rotarix, GlaxoSmithKline) or a three-dose series with RV5 (RotaTeq, Merck) — since 2006. However, on Jan. 5, federal officials changed the recommendation to shared decision-making for the shot and several others.
The American Academy of Pediatrics (AAP) sued

Who owns CKM syndrome? Primary care leads, the team delivers

Cardiovascular-kidney-metabolic syndrome calls on us to connect conditions our healthcare system often treats separately. Ownership has been debated across nephrology and cardiology, but primary care must be central to the discussion.
The announcement of the Kidney Care National Plan by HHS Secretary Robert F. Kennedy Jr. in October brings renewed attention to the need for earlier detection and prevention. This federal strategy creates an opportunity to strengthen three clinical commitments:
The Kidney Health Evaluation for Patients with Diabetes (KED), introduced by the National Committee for

Drug sequencing integral part of osteoporosis care

As osteoporosis treatment options expand, determining the optimal sequence of therapies has become a critical clinical consideration.
There are multiple FDA-approved classes of medications for treating osteoporosis. The two most common classes are bisphosphonates, such as alendronate, risedronate and zoledronic acid, and anabolic drugs, such as abaloparatide (Tymlos, Radius Health), romosozumab-aqqg (Evenity, Amgen) and teriparatide. Another common osteoporosis medication, denosumab, is classified as an antiresorptive medication.
“We now have a few medications for osteoporosis that we can use,”